Wang T., Smith DA., Campbell C., Harris S., Salih H., Várnai KA., Woods K., Noble T., Freeman O., Moysova Z., Marjot T., Webb GJ., Davies J., Barnes E., Matthews PC.

The association of liver biochemistry with clinical outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is currently unclear, and the utility of longitudinally measured liver biochemistry as prognostic markers for mortality is unknown. We aimed to determine whether abnormal liver biochemistry, assessed at baseline and at repeat measures over time, was associated with death in hospitalized patients with COVID-19 compared to those without COVID-19, in a United Kingdom population. We extracted routinely collected clinical data from a large teaching hospital in the United Kingdom, matching 585 hospitalized patients who were SARS-CoV-2 real-time reverse transcription-polymerase chain reaction (RT-PCR) positive to 1,165 hospitalized patients who were RT-PCR negative for age, sex, ethnicity, and preexisting comorbidities. A total of 26.8% (157/585) of patients with COVID-19 died compared to 11.9% (139/1,165) in the group without COVID-19 (P

Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019.

Wang T., Smith DA., Campbell C., Harris S., Salih H., Várnai KA., Woods K., Noble T., Freeman O., Moysova Z., Marjot T., Webb GJ., Davies J., Barnes E., Matthews PC.

DOI

Type

Journal

Publication Date

Volume

Pages